Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q3 2015 Earnings Presentation
7 slides from Anika Therapeutics's earnings presentation, Oct 29, 2015
Slide 1: Third Quarter 2015 Earnings Call Presentation
ANIKA THERAPEUTICS, INC. Third Quarter 2015 Earnings Call Presentation October 29, 2015
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT The statements made in this presentation that are not statements of historical fact are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve known an
Slide 3: Continued Progress on Many Fronts
CONTINUED PROGRESS ON MANY FRONTS Strong End-User Robust Financial Operational Demand Performance Advancements ORTHOVISC Continues $23.7M Total Revenue CINGAL RFD Lead in Multi- Submitted After Injection Market $8.4M Net Income Meeting with FDA MONOVISC is #2 in $0.55 Diluted EPS Consolidating Singl
Slide 4: Pipeline Represents Growth Potential
PIPELINE REPRESENTS GROWTH POTENTIAL • Poised to be First Viscosupplement to Combine HA Formulation with a Well-Established Steroid • Potential to Expand Target Patients on Osteoarthritis (OA) Spectrum • Potential to be First Commercialized Viscosupplement to Treat OA Hip Pain • Expands U.S. Viscosu
Slide 5: Strong Financial Performance
STRONG FINANCIAL PERFORMANCE Top-Line Growth Bottom-Line Growth 8% 37.5% Product Revenue Diluted EPS Driven by Uptick in MONOVISC Sales During Quarter Inventory Reset Concluded in Q3 5
Slide 6: Setting Stage for Next Phases of Growth
SETTING STAGE FOR NEXT PHASES OF GROWTH Developing Direct Appointing Commercialization Richard Hague as Capability in U.S. Chief Commercial Officer Optimize Financial Results and Over Three Decades of Commercial Flexibility via both Direct and Leadership Experience Distributor Models Spearheaded Com
Slide 7: Q&A
Q&A Anika Therapeutics, Inc. Third Quarter 2015 Earnings Call Presentation October 29, 2015